Strategy Asset Managers’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.3M | Buy |
20,278
+497
| +3% | +$508K | 3.63% | 3 |
|
|
2026
Q1 | $18.2M | Sell |
19,781
-231
| -1% | -$234K | 2.99% | 5 |
|
|
2025
Q4 | $21.5M | Buy |
20,012
+1,485
| +8% | +$1.42M | 3.54% | 5 |
|
|
2025
Q3 | $14.1M | Buy |
18,527
+3,211
| +21% | +$2.39M | 2.54% | 6 |
|
|
2025
Q2 | $11.9M | Buy |
15,316
+521
| +4% | +$405K | 2.23% | 9 |
|
|
2025
Q1 | $12.2M | Sell |
14,795
-1,023
| -6% | -$851K | 2.52% | 6 |
|
|
2024
Q4 | $12.2M | Sell |
15,818
-111
| -0.7% | -$91.9K | 2.37% | 7 |
|
|
2024
Q3 | $14.1M | Buy |
15,929
+9,091
| +133% | +$8.17M | 2.71% | 6 |
|
|
2024
Q2 | $3.21M | Sell |
6,838
-8,558
| -56% | -$6.85M | 0.71% | 44 |
|
|
2024
Q1 | $12M | Buy |
15,396
+267
| +2% | +$190K | 2.56% | 5 |
|
|
2023
Q4 | $8.82M | Buy |
15,129
+8,883
| +142% | +$5.19M | 2.09% | 12 |
|
|
2023
Q3 | $3.35M | Sell |
6,246
-592
| -9% | -$305K | 0.88% | 36 |
|
|
2023
Q2 | $3.21M | Buy |
6,838
+39
| +0.6% | +$16.4K | 0.71% | 44 |
|
|
2023
Q1 | $2.33M | Buy |
6,799
+19
| +0.3% | +$6.41K | 0.57% | 46 |
|
|
2022
Q4 | $2.48M | Sell |
6,780
-81
| -1% | -$28.7K | 0.63% | 43 |
|
|
2022
Q3 | $2.22M | Buy |
6,861
+2,669
| +64% | +$846K | 0.6% | 47 |
|
|
2022
Q2 | $1.36M | Sell |
4,192
-8
| -0.2% | -$2.4K | 0.42% | 52 |
|
|
2022
Q1 | $1.2M | Buy |
4,200
+686
| +20% | +$177K | 0.26% | 70 |
|
|
2021
Q4 | $971K | Sell |
3,514
-686
| -16% | -$174K | 0.25% | 72 |
|
|
2021
Q3 | $970K | Buy |
4,200
+686
| +20% | +$169K | 0.22% | 89 |
|
|
2021
Q2 | $807K | Sell |
3,514
-1,470
| -29% | -$295K | 0.17% | 100 |
|
|
2021
Q1 | $931K | Sell |
4,984
-3,535
| -41% | -$691K | 0.21% | 83 |
|
|
2020
Q4 | $1.44M | Sell |
8,519
-861
| -9% | -$129K | 0.34% | 57 |
|
|
2020
Q3 | $1.39M | Buy |
9,380
+3,994
| +74% | +$618K | 0.36% | 57 |
|
|
2020
Q2 | $884K | Buy |
5,386
+398
| +8% | +$61.1K | 0.24% | 73 |
|
|
2020
Q1 | $692K | Sell |
4,988
-5,006
| -50% | -$688K | 0.22% | 77 |
|
|
2019
Q4 | $1.31M | Buy |
9,994
+982
| +11% | +$114K | 0.32% | 53 |
|
|
2019
Q3 | $1.01M | Buy |
9,012
+249
| +3% | +$27.7K | 0.3% | 51 |
|
|
2019
Q2 | $971K | Sell |
8,763
-13,118
| -60% | -$1.54M | 0.27% | 55 |
|
|
2019
Q1 | $2.84M | Buy |
21,881
+19,072
| +679% | +$2.32M | 0.64% | 43 |
|
|
2018
Q4 | $325K | Buy |
2,809
+130
| +5% | +$14.5K | 0.08% | 115 |
|
|
2018
Q3 | $287K | Hold |
2,679
| – | – | 0.06% | 123 |
|
|
2018
Q2 | $229K | Buy |
+2,679
| New | +$220K | 0.05% | 120 |
|
|
2018
Q1 | – | Sell |
-2,679
| Closed | -$226K | – | 127 |
|
|
2017
Q4 | $226K | Hold |
2,679
| – | – | 0.04% | 125 |
|
|
2017
Q3 | $229K | Hold |
2,679
| – | – | 0.05% | 124 |
|
|
2017
Q2 | $220K | Hold |
2,679
| – | – | 0.05% | 123 |
|
|
2017
Q1 | $225K | Hold |
2,679
| – | – | 0.05% | 119 |
|
|
2016
Q4 | $200K | Hold |
2,679
| – | – | 0.04% | 124 |
|
|
2016
Q3 | $215K | Sell |
2,679
-18,815
| -88% | -$1.51M | 0.05% | 123 |
|
|
2016
Q2 | $1.69M | Sell |
21,494
-6,264
| -23% | -$472K | 0.38% | 81 |
|
|
2016
Q1 | $2M | Sell |
27,758
-29
| -0.1% | -$2.19K | 0.45% | 80 |
|
|
2015
Q4 | $2.34M | Buy |
27,787
+154
| +0.6% | +$12.8K | 0.53% | 64 |
|
|
2015
Q3 | $2.31M | Buy |
27,633
+24,889
| +907% | +$2.1M | 0.56% | 57 |
|
|
2015
Q2 | $229K | Buy |
+2,744
| New | +$209K | 0.05% | 130 |
|
Other funds holding LLY
Strategy Asset Managers's LLY Position: Q2 2026 in Review
Strategy Asset Managers increased its Eli Lilly (LLY) stake by 2.5% in Q2 2026, buying an estimated $508K and bringing the position to 20,278 shares worth $24.3M. The position accounts for 3.63% of the portfolio, ranked #3.
Strategy Asset Managers first reported a position in LLY in Q2 2015 and has held it in 44 quarters since. 4,599 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Strategy Asset Managers held 20,278 shares of Eli Lilly worth $24.3M as of Q2 2026.
- Strategy Asset Managers bought 497 Eli Lilly shares in Q2 2026, an estimated $508K.
- Eli Lilly made up 3.63% of Strategy Asset Managers's portfolio in Q2 2026, its #3 holding.
- Strategy Asset Managers first reported a position in Eli Lilly in Q2 2015 and has held it in 44 quarters since.
- 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Strategy Asset Managers's 13F filing for Q2 2026, filed 14 Aug 2026.